Krsnaa Diagnostics Q1 FY27: Growth Holds Up, But Rajasthan Ramp Costs Hit Margins

Krsnaa Diagnostics opened FY27 with a mix of strong top line momentum and near-term profitability pressure. In Q1 FY27, consolidated revenue from operations rose to INR 2,355 million, up 22% year on year from INR 1,930 million. EBITDA before CSR and ESOP was INR 588 million, translating into a 25% margin versus 27% in Q1 FY26. Profit after tax fell to INR 166 million from INR 205 million, as the company carried upfront fixed costs for new project rollouts and absorbed higher finance costs and depreciation.

Management’s central message was consistent across the investor presentation and the earnings call. The business model is infrastructure-led, with capital and operating costs front-ended before volumes ramp. The current quarter reflects that rhythm, particularly in Rajasthan, where the company has been building a large pathology network. Management argued that like-to-like operations remained stable, while the reported margin compression was tied to ramp-up projects rather than structural pressure in the core business.

Financial performance: Revenue growth, margin moderation

The quarter’s consolidated P&L highlights the trade-off between scaling and near-term margins. Total expenses rose to INR 1,767 million, or 75% of revenue, versus 73% in the year-ago quarter. Among key line items, “fees to hospitals and others” rose sharply to INR 406 million from INR 154 million. On the call, management clarified that the line includes revenue-share payouts to local partners used for operations in remote locations, and Rajasthan was a major driver.

The company also reported a higher finance cost of INR 148 million compared to INR 63 million in Q1 FY26, and depreciation increased to INR 280 million from INR 216 million. These factors, combined with the operating cost base carried ahead of utilization in Rajasthan, drove PAT margin down to 7% from 11%.

The company also reiterated that quarterly results can be cyclical, and that performance is best monitored on an annual basis.

Rajasthan: From implementation to operations

Rajasthan remains the most important near-term driver of both growth and margin trajectory. Management described Q1 FY27 as a transition from implementation to go-live. As of the end of the quarter, the company stated that Rajasthan had 31 mother labs, 62 hub labs, and 1,228 collection centers operational. This network scale is intended to create the base for utilization-led operating leverage.

However, the quarter also reflects the cost of building that foundation. On the call, the CFO noted that the company onboarded around 4,000 manpower in Rajasthan and built logistics across collection centers ahead of full revenue realization. Management expects this impact to normalize as Rajasthan revenue scales through the year.

On revenue visibility, management disclosed that Rajasthan contributed around INR 26 crore in Q1 FY27. For FY27, the company offered a conservative revenue range of INR 100 to 150 crore from Rajasthan, while also stating that the revenue should grow as more labs and centers go live. In the same discussion, management indicated hopes of Rajasthan revenues doubling in coming quarters as ramp-up continues.

Retail (RPL): Fast growth, profitability still developing

Retail diagnostics is being positioned as the company’s second growth engine alongside institutional PPP business. In Q1 FY27, retail revenue increased to INR 193 million from INR 118 million in Q1 FY26, a 64% year-on-year rise. Management said retail contributed about 9% of overall group revenue for the quarter.

The investor presentation highlighted that retail patient count rose to 0.21 million from 0.12 million, and retail test volume increased to 0.47 million from 0.32 million. Retail revenue per patient was broadly steady at INR 931 versus INR 950.

Profitability, however, is still in transition. Management stated that RPL was negative EBITDA in Q1 due to manpower deployment required to scale operations across states. They expect RPL to be EBITDA positive by Q2, and described the current drag as lower than earlier quarters.

Operationally, the retail push is being built through a mix of franchise models, collection networks, home collection, wellness camps, digital channels, and partnerships. Management emphasized that retail is not being built in isolation, but is leveraging the existing PPP ecosystem including labs, radiologists, pathologists, technology and logistics.

Radiology execution and new project wins

On radiology expansion, management spoke about execution progress against an order pipeline of 17 MRI centers. Eight MRI centers in Maharashtra were inaugurated and operationalized during Q1. The balance centers are expected to go live by the end of Q3.

The company also announced a new award in Himachal Pradesh for a CT project spanning 34 locations, expanding from its earlier footprint of 12 centers in the state. Management said the project provides revenue visibility for the next 10 years and could extend the relationship in the state to about 25 years in total. They also indicated that much of the project may be cash paying, although they did not provide revenue or capex specifics, stating that discussions were still ongoing.

Quality and accreditation as a differentiator

Krsnaa continues to emphasize accreditation and quality credentials as a competitive advantage. The presentation highlighted 120 total accreditations (66 NABH accredited centers and 54 NABL accredited labs). On the call, management said the overall count including NABL, CAP and ACR reached 124 after adding 12 NABH accreditations in Q1.

The company positioned itself as an accreditation leader among peers, claiming a significantly higher combined accreditation footprint based on its internal peer comparison shared in the presentation.

What to track from here

Management’s guidance for the coming quarters centered on ramp-up and utilization. They expect margins to improve quarter on quarter as Rajasthan revenues scale and retail turns EBITDA positive. They also stated an expectation that margins return to double digits by the end of the year as a whole.

The company flagged that receivable collections were not fully normalized in Karnataka, while in Himachal Pradesh certain funds had been allocated and collections had started flowing. These working capital movements remain an important monitorable given the PPP exposure.

Overall, Q1 FY27 reinforced Krsnaa’s strategic direction. The platform continues to expand across radiology and pathology, retail is showing visible traction, and Rajasthan is moving from build-out to operations. The key investment debate now hinges on how quickly utilization improves, because that will determine how fast the company can convert infrastructure creation into sustainable profitability.